Search

Objective To evaluate the safety and efficacy of acupoint autohemotherapy（AA）. Methods We collected Controlled Trials that are random of AA plus medicine of the west therapy vs western medicine therapy alone in treating COPD from PubMed, the Cochrane library, EMBASE, CNKI, CBM SinoMed, China Science, and Wanfang Data from database inception to July 1, 2019. Meta-analysis was performed using the RevMan 5.3. Results This meta-analysis identified that the combined treatment could enhance the total effective clinical rate, the forced expiratory volume in 1 s（FEV1）and forced vital capacity（FVC），increase the 6-min walking distance，and improve the self-assessment of chronic obstructive pulmonary disease score（CAT）. Conclusion The clinical effects of AA plus medicine of the west therapy are better than that of western medicine alone in treating COPD. However, due to the small number and poor quality of the included RCTs，this conclusion needs to be verified with larger samples and higher quality RCTs.

Background:Patients with simple obesity suffer from poor quality of life, as well as high risk of hypertension, diabetes, cardiovascular, and cerebrovascular accidents. Lots of Clinical trials suggested that acupuncture is beneficial for simple obesity, and it aims to gather solid evidence i

Background Chronic Obstructive Pulmonary Disease (COPD) is a clinically common chronic disease with the characteristic of recurrent attacks, difficulty of cure and high morbidity, disability, death rates. COPD exerts a great burden on patients, families and society. Acupoint Autohemotherapy (AA) is a traditional Chinese medicine (TCM) treatment by taking the patient's own venous blood and injecting them at acupoints, combined with the continuous stimulation of blood and the specific efficacy of the acupoint itself. It has been proved to be useful in pulmonary treatment and rehabilitation of COPD patients. However, the efficacy of AA on COPD patients has not been fully statistically evaluated. In this study, we aim to systematically examine the efficacy and safety of AA for COPD patients. Methods Data from all English and Chinese databases, including Medline, Cochrane Library, Embase, China National Knowledge Infrastructure Database, Wanfang Database, China Biomedical Literature Database and Chongqing VIP information, will be used to conduct a systematic and comprehensive literature search. The range of date is from inception to July 2019. Randomized controlled trials (RCTs) related to AA and western medicine in the treatment of COPD will be included. Quality of included trials will be assessed according to the risk of bias tool of Cochrane Handbook 5.1.0. The GRADE approach will be used to rate the certainty of the evidence of estimates derived from meta-analysis. RevMan 5.3 will be used for data synthesis, sensitivity analysis, meta-regression analysis, subgroup analysis and risk of bias assessment. A funnel plot will be developed to evaluate reporting bias, and Begg and Egger tests will be used to assess funnel plot symmetries. Grading of recommendations assessment, development and evaluation system will be utilized to assess the quality of evidence. Results This systematic review and meta-analysis aims to summarize the direct and indirect outcomes for AA and western medicine on COPD patients and evaluate its efficacy and safety. The results will be submitted to a peer-reviewed journal once completed. Conclusion The systematic review will provide evidence to assess the efficacy and safety of AA and western medicine in the treatment of COPD patients. Prospero registration number PROSPERO CRD42019137189.